Evidence map›Paper›PMID 42553276›Full record

ArticleFrontiers in pharmacology2026

Influence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot study.

Michelangelo Rottura, Igor Pirrotta, Chiara Cullotta, Ylenia Marino, Federica Maria Sacco, Viviana Maria Gianguzzo, Natasha Irrera, Vincenzo Arcoraci, Angela Alibrandi, Francesca Galletta and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michelangelo RotturaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Igor PirrottaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Chiara CullottaDepartment of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
Ylenia MarinoDepartment of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
Federica Maria SaccoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Viviana Maria GianguzzoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Natasha IrreraDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Vincenzo ArcoraciDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Angela AlibrandiDepartment of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, Messina, Italy.
Francesca GallettaDepartment of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, Messina, Italy.
Marzia CorsoPediatric Unit, University Hospital "Gaetano Martino", Messina, Italy.
Salvatore LeonardiPediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Sara MantiDepartment of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, Messina, Italy.
Giovanni PallioDepartment of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Severe asthma affects 3%-5% of children and may remain uncontrolled despite high-dose inhaled corticosteroids and other controller therapies. Omalizumab, an anti-IgE monoclonal antibody, is approved for children ≥6 years with severe asthma, however treatment response shows substantial interindividual variability. Objectives: This study aimed to investigate whether selected single nucleotide polymorphisms (SNPs) in genes involved in IgE signaling and immune regulation are associated with clinical response to omalizumab in pediatric severe asthma. Methods: In this retrospective cohort study, 30 children with severe asthma treated with omalizumab for 12 months were genotyped for selected SNPs in Results: FEV1% improvement showed a nominal association with the variant allele of Conclusion: Genetic variability in IgE- and Fc receptor-related pathways may contribute to differential response to omalizumab in children with severe asthma. These findings are exploratory and require validation in larger prospective studies.

Indexed as

biologic therapyomalizumabpersonalized medicinepharmacogeneticssevere pediatric asthmasingle nucleotide polymorphisms (SNPs)

Identifiers

PMID42553276
PMCPMC13433449

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.